Hospital Santa Creu i Sant Pau, Barcelona, Spain.
EBMT Data Office, Leiden, The Netherlands.
Bone Marrow Transplant. 2017 Aug;52(8):1107-1112. doi: 10.1038/bmt.2017.19. Epub 2017 Mar 20.
This study shows the long-term updated outcomes of a multicenter retrospective study which analyzed 843 patients with myelodysplastic syndrome (MDS) who underwent transplantation with an HLA-identical sibling donor with either reduced-intensity conditioning (RIC) in 213 patients, or standard myeloablative conditioning (MAC) in 630 patients. In multivariate analysis, the 13-year relapse rate was significantly increased after RIC (31% after MAC vs 48% in RIC; HR, 1.5; 95% CI, 1.1-1.9; P=0.04), but with no differences in overall survival (OS) (30% after MAC vs 27% in RIC; P=0.4) and PFS (29 vs 21%, respectively, P=0.3). Non-relapse mortality was higher in MAC (40 vs 31%; P=0.1), especially in patients older than 50 years (50 vs 33%, P<0.01). In addition, long-term follow-up confirms the importance of other variables on 13-year OS, mainly MDS risk category, disease phase, cytogenetics and receiving a high donor cell dose, irrespective of the conditioning regimen used.
本研究展示了一项多中心回顾性研究的长期更新结果,该研究分析了 843 例接受 HLA 匹配的同胞供者移植的骨髓增生异常综合征(MDS)患者,其中 213 例患者接受了低强度预处理(RIC),630 例患者接受了标准的清髓性预处理(MAC)。多因素分析显示,RIC 后 13 年的复发率显著增加(MAC 后为 30%,RIC 后为 48%;HR,1.5;95%CI,1.1-1.9;P=0.04),但总生存(OS)和无进展生存(PFS)无差异(MAC 后分别为 30%和 27%,RIC 后分别为 27%和 21%,P=0.3)。MAC 组非复发死亡率较高(40%比 31%;P=0.1),尤其是年龄大于 50 岁的患者(50%比 33%,P<0.01)。此外,长期随访证实了其他变量对 13 年 OS 的重要性,主要是 MDS 危险类别、疾病阶段、细胞遗传学和接受高供者细胞剂量,而与预处理方案无关。